Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human SPRY2 Anticorps:
anti-Mouse (Murine) SPRY2 Anticorps:
anti-Rat (Rattus) SPRY2 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal SPRY2 Primary Antibody pour IF, IHC (p) - ABIN564439
Barbáchano, Ordóñez-Morán, García, Sánchez, Pereira, Larriba, Martínez, Hernández, Landolfi, Bonilla, Pálmer, Rojas, Muñoz: SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. dans Oncogene 2010
Show all 3 Pubmed References
Human Polyclonal SPRY2 Primary Antibody pour ELISA, WB - ABIN1043909
August: Cerebrovascular and carotid artery disease. dans Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2001
Show all 2 Pubmed References
Cow (Bovine) Polyclonal SPRY2 Primary Antibody pour WB - ABIN2784218
Hsu, Lee, Hartstein, Harocopos: Clostridium perfringens Keratitis Leading to Blinding Panophthalmitis. dans Cornea 2008
Show all 2 Pubmed References
Cow (Bovine) Polyclonal SPRY2 Primary Antibody pour IHC, WB - ABIN2784217
Lee, Ho, Roy, Kosinski, Patil, Tward, Fridlyand, Chen: Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. dans Hepatology (Baltimore, Md.) 2008
Show all 2 Pubmed References
Human Polyclonal SPRY2 Primary Antibody pour ELISA, ICC - ABIN4355751
Zhang, Chaturvedi, Jaggar, Magnuson, Lee, Patel: Regulation of vascular smooth muscle cell proliferation and migration by human sprouty 2. dans Arteriosclerosis, thrombosis, and vascular biology 2005
Data show that the intracellular domain of PAPC interacts with Sprouty (Spry), and upon binding to PAPC, Spry function is inhibited and PCP signaling is enhanced.
Here we show that Xenopus laevis Sprouty2 (XSpry2) controls the duration of ERK (Montrer MAPK1 Anticorps) activity and thereby contributes to the establishment of dorsoventral patterning during mesoderm formation.
Overexpression of miR (Montrer MLXIP Anticorps)-592 promotes GC proliferation, migration, and invasion and induces the EMT (Montrer ITK Anticorps) via the PI3K (Montrer PIK3CA Anticorps)/AKT (Montrer AKT1 Anticorps) and MAPK/ERK (Montrer MAPK1 Anticorps) signaling pathways by inhibiting Spry2, suggesting a potential therapeutic target for Gastric cancer.
nuclear Spry2 acts as a molecular link which co-ordinates airway and vascular growth of the cardiopulmonary system.
activation of ERK1/2 signaling was required for hCG-induced up-regulation of SPRY2 expression. Further, SPRY2 knockdown attenuated the AREG-induced COX-2 expression and PGE2 production by inhibiting AREG-activated ERK1/2 signaling.
Result demonstrated that SPRY2 low-expression was significantly associated with unfavorable prognosis of gastric adenocarcinoma and that SPRY2 could inhibit FGFR2 (Montrer FGFR2 Anticorps)-induced ERK (Montrer EPHB2 Anticorps) phosphorylation and suppress FGFR2 (Montrer FGFR2 Anticorps)-elicited gastric cancer cell proliferation and invasion.
Sprouty2 inhibits amphiregulin (Montrer AREG Anticorps)-induced down-regulation of E-cadherin (Montrer CDH1 Anticorps) and cell invasion in human ovarian cancer cells.
Sprouty2 (Spry2), a negative regulator of the extracellular signal regulated kinase/mitogen-activated protein kinase (Montrer MAPK1 Anticorps) (Erk/MAPK (Montrer MAPK1 Anticorps)) signalling pathway, was a downstream target of miR (Montrer MLXIP Anticorps)-122-5p possibly involved in regulating the keratinocyte proliferation.
results shows the involvement of Spry2 in regulation of FosB (Montrer FOSB Anticorps) and Runx2 (Montrer RUNX2 Anticorps) genes, MAPK (Montrer MAPK1 Anticorps) signaling and proliferation of mesenchymal stem cells.
MYB (Montrer MYB Anticorps) acts on MAPK (Montrer MAPK1 Anticorps) signaling by directly regulating transcription of the gene encoding the negative modulator SPRY2.
ZEB1 (Montrer ZEB1 Anticorps) upregulation by SPRY2 results from the combined induction of ETS1 (Montrer ETS1 Anticorps) transcription factor and the repression of microRNAs (miR (Montrer MLXIP Anticorps)-200 family, miR (Montrer MLXIP Anticorps)-150) that target ZEB1 (Montrer ZEB1 Anticorps) RNA. Moreover, SPRY2 increased AKT (Montrer AKT1 Anticorps) activation by epidermal growth factor (Montrer EGF Anticorps), whereas AKT (Montrer AKT1 Anticorps) and also Src (Montrer SRC Anticorps) inhibition reduced the induction of ZEB1 (Montrer ZEB1 Anticorps).
upregulated in human CRC (Montrer CALR Anticorps). Suppression of SPRY2 repressed AKT2 (Montrer AKT2 Anticorps) and EMT (Montrer ITK Anticorps)-inducing transcription factors and significantly increased E-cadherin (Montrer CDH1 Anticorps) expression. Concurrent downregulation of SPRY1 (Montrer SPRY1 Anticorps) and SPRY2 also increased E-cadherin (Montrer CDH1 Anticorps) and suppressed mesenchymal markers in colon cancer cells.
Loss of Spry1 (Montrer SPRY1 Anticorps)/2 enhances the survival of effector CD8 (Montrer CD8A Anticorps)+ T cells and results in the formation of more protective memory cells. Deleting Spry1 (Montrer SPRY1 Anticorps)/2 in antigen-specific CD8 (Montrer CD8A Anticorps)+ T cells may have therapeutic potential for enhancing the survival and functionality of effector and memory CD8 (Montrer CD8A Anticorps)+ T cells in vivo.
These results identify Spry2 as a critical regulator of endochondral bone formation that modulates signaling in both osteoblast and chondrocyte lineages.
Spry2 is a novel unfolded protein response target and its upregulation is dependent on PERK (Montrer EIF2AK3 Anticorps). Knockdown of Spry2 resulted in reduced expression of Serca2 (Montrer ATP2A2 Anticorps), reduced endoplasmic reticulum calcium levels, and induction of the UPR. Spry2 deletion in the adult mouse beta-cell caused hyperglycemia and hypoinsulinemia.
these results establish SPRY2 as a critical negative regulator of BCR (Montrer BCR Anticorps)-mediated MAPK-Erk (Montrer MAPK1 Anticorps) signaling in chronic lymphocytic leukemia , thereby providing one of the molecular mechanisms to explain the clinical heterogeneity of chronic lymphocytic leukemia.
In the present study, it is demonstrated that Spry2 and -4 participate in KA induced neurodegeneration possibly through inhibition of ERK (Montrer EPHB2 Anticorps) signaling.
Study revealed that suppression of Spry2 expression induced proliferation and differentiation of osteoblastic cells upon bFGF (Montrer FGF2 Anticorps) and EGF (Montrer EGF Anticorps) stimulation, whereas it diminished proliferation of gingival epithelial cells.
Cosuppression of Sprouty and Sprouty-related negative regulators of FGF signalling in prostate cancer
in embryos with lower Spry2;Spry4 (Montrer SPRY4 Anticorps) gene dosages, we observed a non-fusion of original R2 and M1 Shh (Montrer SHH Anticorps) signaling domains with consequent formation of a supernumerary tooth primordium from the isolated R2 bud
The data showed enhanced axon outgrowth and improved long-distance axon regeneration in sprouty2 deficient mice
This gene encodes a protein belonging to the sprouty family. The encoded protein contains a carboxyl-terminal cysteine-rich domain essential for the inhibitory activity on receptor tyrosine kinase signaling proteins and is required for growth factor stimulated translocation of the protein to membrane ruffles. In primary dermal endothelial cells this gene is transiently upregulated in response to fibroblast growth factor two. This protein is indirectly involved in the non-cell autonomous inhibitory effect on fibroblast growth factor two signaling. The protein interacts with Cas-Br-M (murine) ectropic retroviral transforming sequence, and can function as a bimodal regulator of epidermal growth factor receptor/mitogen-activated protein kinase signaling. This protein may play a role in alveoli branching during lung development as shown by a similar mouse protein.
protein sprouty homolog 2
, sprouty 2